Table 4 Factors associated with non-regression of liver fibrosis stage based on LSM between SVR24 and SVR96 in HCV-infected patients treated with DAAs.

From: Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

 

Regression

Non-regression

Univariate analysis

Multivariate analysis

Odds ratio

Number

93

17

   

Age (years)a

67 (23–84)

67 (57–88)

0.305

  

Sex (male/female)

36/57

5/12

0.466

  

DCV/ASV, SOF/LDV, SOF/RBV, OBV/PTV/r

14/42/33/4

5/5/6/1

0.452

  

HCV-RNA (log IU/mL)a

N.D

N.D

–

  

Baseline BMI (kg/m2)a

22 (15.8–36.3)

22.5 (15.8–31.2)

0.828

  

Obesity (BMI ≧ 25 kg/m2) (n, %)

19 (20%)

5 (29%)

0.296

  

F0-2/3–4 at SVR24

81/12

6/11

* < 0.001

 < 0.001

12.35 (3.86–39.6)

Platelet count (× 104)a at SVR24

17.8 (3.6–34.1)

13.8 (4.8–24.3)

*0.004

  

AST (IU/L)a at SVR24

21 (11–50

26 (17–128)

*0.003

  

ALT (IU/L)a at SVR24

14 (5–50)

16 (9–121)

0.104

  

γGTP (IU/L)a at SVR24

16 (9–92)

22 (8–865)

*0.019

  

FIB-4 indexa at SVR24

2.07 (0.5–9.35)

3.32 (1.92–9.01)

* < 0.001

0.107

 

Angiopoietin-2 at SVR24 (pg/mL)a

266 (60.2–774.4)

416.6 (219.1–913)

*0.001

0.088

 

CAP (dB/m)a at SVR24

219 (122–385)

228 (145–301)

0.761

  

Liver steatosis (CAP > 248 dB/m) (n, %)

19 (20%)

1 (6%)

0.135

  

Alcohol drinking (n, %)

10 (11%)

3 (18%)

0.322

  

Diabetes mellitus (n, %)

17 (18%)

5 (29%)

0.228

  

High blood pressure (n, %)

27 (29%)

11 (65%)

*0.006

  

Dyslipidaemia (n, %)

19 (14%)

1 (6%)

0.135

  
  1. HCV hepatitis C virus, BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyl transpeptidase, FIB-4 fibrosis 4, CAP Controlled Attenuation Parameter. aData are shown as median (range) values. *Statistically significant difference, P < 0.05.
Back to article page